Prosecution Insights
Last updated: November 04, 2026
Application No. 18/716,263

METHOD FOR SCREENING TUBERCULOSIS-INFECTED SAMPLE AND PROBE SET TO BE USED THEREFOR

Non-Final OA §102§112
Filed
Jun 04, 2024
Priority
Dec 21, 2021 — JP 2021-207106 +1 more
Examiner
DAUNER, JOSEPH G
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kansai Medical University Educational Corporation
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
422 granted / 742 resolved
-3.1% vs TC avg
Strong +36% interview lift
Without
With
+35.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
54 currently pending
Career history
824
Total Applications
across all art units

Statute-Specific Performance

§101
12.6%
-27.4% vs TC avg
§103
28.4%
-11.6% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
32.4%
-7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 742 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The amended claims dated 8/5/2026 are under consideration. Election/Restrictions Applicant’s election without traverse of Group II, claims 13-14, in the reply filed on 8/5/2026 is acknowledged. New claims 15 and 16 depend from claims 13 and 14 and are included with the election of Group II. Claims 9-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 8/5/2026. Applicant’s election of labeled probes that hybridize with hsa-miR-423-5p, hsa-miR-532-3p and hsa-miR-423-3p in the reply filed on 8/5/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Priority The present application is a 371 national stage entry of PCT/JP2022/046903 (filed 12/20/2022) and claims benefit to foreign application JAPAN 2021-20710 (filed 12/21/2021). It is noted that an English translation of the foreign priority document has not been received. Information Disclosure Statement The listing of references in the specification or the citation of references throughout the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892 or a submitted IDS, they have not been considered. Drawings High resolution copies of the drawings may be accessed via PAIR/Patent Center Retrieval using the Supplemental Content tab. Specification The disclosure is objected to because of the following informalities: the specification uses “sequence of ID:…” rather than “SEQ ID NO:…”. Appropriate correction is required. The use of terms, such as Magtration, MagMax, GeneXpert, etc., which are trade names or marks used in commerce, has been noted in this application. The terms should be accompanied by the generic terminology; furthermore the terms should be capitalized wherever they appear or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM , or ® following the term. Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. The hyperlink appears in paragraph 40. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 15 and 16 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Regarding claims 15 and 16, the claims further describe the “screening” recited in the preamble of claims 13 and 14. The claims are drawn to products and a description of an intended use does not further limit the scope of the structure of the probes of claims and 13 and 14. In other words, the structure of the probes of claims 15 and 16 encompass the same subject matter as claims 13 and 14. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 13-16 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Naqvi (J Microb Biochem Technol. 2016. 8(2):136-143). Regarding claims 13 and 14, Naqvi teaches probes as part of a multiplexed, color-coded probe assay for miRNA profiling (p. 137, nCounter miRNA expression assay). The probes include those specific for hsa-miR-532-3p (p. 140, B. Human macrophages treated with 1 ng/ml E. coli LPS for 8 hours and D. Human macrophages treated with 10ng/ml E. coli LPS for 8 hour), hsa-miR-423-5p (p. 140, B. Human macrophages treated with 1 ng/ml E. coli LPS for 8 hours), and hsa-miR-423-3p (p. 140, D. Human macrophages treated with 10ng/ml E. coli LPS for 8 hour). It is noted the sequence of hsa-miR-423-3p and hsa-miR-532-3p are: hsa-miR-423-3p = AGCUCGGUCUGAGGCCCCUCAGU; and hsa-miR-532-3p = CCUCCCACACCCAAGGCUUGCA as evidenced by MirBase. The known sequences of hsa-miR-532-3p and hsa-miR-423-3p are substantially similar to claimed SEQ ID NOs: 49 and 56. Thus, the labeled probes used by Naqvi hybridize with one or more nucleotides of SEQ ID NOs: 49 and 56 because if they did not, Naqvi would not have been able to measure the amounts of the reported miRNA. Regarding claims 15-16, the claims further describe the “screening” aspect in the preamble of claims 13 and 14. Claims 15 and 16 are product claims, and claim language describes how the probes may be used, e.g., describing the “screening” they are intended to be used in. Thus, claims 15 and 16 do not limit the structure of the probes required by claims 13 and 14, and thus, claims 15 and 16 are also anticipated for the same reason as claims 13 and 14. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH G DAUNER whose telephone number is (571)270-3574. The examiner can normally be reached 7 am EST to 4:30 EST with second Fridays Off. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng Winston Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOSEPH G. DAUNER/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Jun 04, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766158
Methods of Treatments Based Upon Anthracycline Responsiveness
5y 0m to grant Granted Oct 20, 2026
Patent 12767990
EPLIN AS A BIOMARKER FOR CANCER
4y 0m to grant Granted Oct 20, 2026
Patent 12767976
NUCLEIC ACID CONTROL MOLECULES FROM NON-HUMAN ORGANISMS
2y 7m to grant Granted Oct 20, 2026
Patent 12760372
METHODS AND KITS FOR DETERMINING THE RISK OF BREAST CANCER RECURRENCE
4y 0m to grant Granted Oct 13, 2026
Patent 12760359
METHODS AND SYSTEMS FOR DETERMINING SEQUENCING READ DISTANCES
3y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
92%
With Interview (+35.5%)
3y 2m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 742 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month